Literature DB >> 8258643

Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma.

E Ciccarelli1, M R Valetto, E Vasario, T Avataneo, S Grottoli, F Camanni.   

Abstract

Nineteen acromegalic patients (12 females and 7 males, aged 24-71 yr) were studied for 1-6 yr after radiotherapy (RT), administered by X-rays (18 MeV) by linear accelerator, with parallel opposite beams (doses 45-50.4 Gy, 1.8 Gy daily). Basal GH levels gradually decreased from 6.3-76.2 micrograms/L (mean +/- SE, 27.8 +/- 4.9) to 0.3-43.4 micrograms/L (11.7 +/- 3.6 micrograms/L; p < 0.005) at the last assessment. The earliest significant decrease was observed after one yr (14.9 +/- 3.8 micrograms/L; p < 0.005). Significant changes were observed also in IGF-I values (basal values 1.93-6.85 mU/ml, 3.22 +/- 0.30; last assessment 0.55-4.57 mU/mL, 1.58 +/- 0.31; p < 0.01). The earliest significant decrease of IGF-I values was observed after 2 yr (1.61 +/- 0.16 mU/ml; p < 0.005). GH levels < 5 micrograms/L together with normal IGF-I values were observed in 9 patients, 2-4 yr after RT. No changes were observed in PRL values, either in patients with pretreatment normal or elevated PRL levels. The CT and/or MRI picture of macroadenoma disappeared after 6-12 months in 3/12 patients. Moreover, a reduction (20-55%) in the diameter of the adenoma was shown after 6-36 months in other 4 patients. After RT 5/16 (31%) patients required cortisol and 4/19 (21%) thyroid replacement therapy. In 2/3 men a gonadal impairment was shown, that did not occur in the three female patients with normal gonadal function before RT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258643     DOI: 10.1007/bf03347671

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  IMMUNOASSAY OF HUMAN GROWTH HORMONE IN PLASMA.

Authors:  S M GLICK; J ROTH; R S YALOW; S A BERSON
Journal:  Nature       Date:  1963-08-24       Impact factor: 49.962

Review 2.  Radiation oncogenesis in relation to the treatment of pituitary tumours.

Authors:  A Jones
Journal:  Clin Endocrinol (Oxf)       Date:  1991-11       Impact factor: 3.478

3.  Growth hormone dynamics in acromegaly.

Authors:  A M Lawrence; I D Goldfine; L Kirsteins
Journal:  J Clin Endocrinol Metab       Date:  1970-09       Impact factor: 5.958

4.  How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors?

Authors:  C M Feek; J McLelland; J Seth; A D Toft; W J Irvine; P L Padfield; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1984-04       Impact factor: 3.478

5.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

Authors:  W H Daughaday; I K Mariz; S L Blethen
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

6.  Radiation-induced hyperprolactinaemia in a treated acromegalic.

Authors:  S M Shalet; I A MacFarlane; C G Beardwell
Journal:  Clin Endocrinol (Oxf)       Date:  1979       Impact factor: 3.478

7.  Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly.

Authors:  A Barreca; E Ciccarelli; F Minuto; P Bruzzi; G Giordano; F Camanni
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05

8.  Conventional supervoltage irradiation is an effective treatment for acromegaly.

Authors:  R C Eastman; P Gorden; J Roth
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

9.  The serum half-life of somatomedin activity: evidence for growth hormone dependence.

Authors:  K L Cohen; S P Nissley
Journal:  Acta Endocrinol (Copenh)       Date:  1976-10

10.  Growth hormone producing pituitary adenomas with concomitant hypersecretion of prolactin are particularly sensitive to photon irradiation.

Authors:  S Werner; E af Trampe; P Palacios; I Lax; K Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-09       Impact factor: 7.038

View more
  3 in total

Review 1.  Reevaluation of conventional pituitary irradiation in the therapy of acromegaly.

Authors:  C A Jaffe
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  Different Volumetric Measurement Methods for Pituitary Adenomas and Their Crucial Clinical Significance.

Authors:  Chi-Cheng Chuang; Shinn-Yn Lin; Ping-Ching Pai; Jiun-Lin Yan; Cheng-Hong Toh; Shih-Tseng Lee; Kuo-Chen Wei; Zhuo-Hao Liu; Chung-Ming Chen; Yu-Chi Wang; Cheng-Chi Lee
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

3.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.